$MYO
MYOMO, INC.

2019 Q4 Form 10-K Financial Statement

#000156459020010809 Filed on March 13, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q1 2019
Revenue $1.521M $830.1K $3.838M
YoY Change 70.95% 165.05% 57.02%
Cost Of Revenue $424.7K $176.2K $1.421M
YoY Change 87.75% 63.02% 95.09%
Gross Profit $1.096M $653.9K $2.417M
YoY Change 65.22% 218.81% 40.86%
Gross Profit Margin 72.08% 78.77% 62.98%
Selling, General & Admin $3.234M $2.801M $11.46M
YoY Change 12.74% 25.31% 10.16%
% of Gross Profit 295.09% 428.43% 474.25%
Research & Development $442.5K $535.3K $1.750M
YoY Change -16.45% 43.75% -4.85%
% of Gross Profit 40.37% 81.86% 72.38%
Depreciation & Amortization $24.44K $21.63K $95.12K
YoY Change 17.22% 48.14% 36.51%
% of Gross Profit 2.23% 3.31% 3.94%
Operating Expenses $3.677M $3.337M $13.21M
YoY Change 8.19% 27.94% 7.9%
Operating Profit -$2.581M -$2.683M -$10.80M
YoY Change -5.64% 11.65% 2.53%
Interest Expense -$180.7K $42.77K -$1.140K
YoY Change -519.53% 1.37% -99.35%
% of Operating Profit
Other Income/Expense, Net $84.74K $81.99K
YoY Change 47.38% -61.26%
Pretax Income -$2.762M -$2.598M -$10.71M
YoY Change 2.58% 10.56% 3.84%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.762M -$2.598M -$10.71M
YoY Change 2.58% 10.77% 3.84%
Net Earnings / Revenue -181.59% -312.99% -279.15%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.812M -$5.216M -$19.35M
COMMON SHARES
Basic Shares Outstanding 17.20M 17.08M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q1 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.465M $9.234M $4.465M
YoY Change -31.73% -34.61% -31.73%
Cash & Equivalents $4.465M $9.309M $4.465M
Short-Term Investments
Other Short-Term Assets $820.2K $784.7K $820.2K
YoY Change 17.97% 112.09% 17.97%
Inventory $439.5K $171.5K $439.5K
Prepaid Expenses
Receivables $424.3K $399.9K $424.3K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.149M $10.72M $6.149M
YoY Change -21.91% -27.96% -21.91%
LONG-TERM ASSETS
Property, Plant & Equipment $155.0K $173.1K $155.0K
YoY Change -17.35% 11.44% -17.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $294.2K $207.0K $294.2K
YoY Change 34.0% 313.96% 34.0%
Total Long-Term Assets $449.2K $380.1K $449.2K
YoY Change 10.35% 83.32% 10.35%
TOTAL ASSETS
Total Short-Term Assets $6.149M $10.72M $6.149M
Total Long-Term Assets $449.2K $380.1K $449.2K
Total Assets $6.599M $11.10M $6.599M
YoY Change -20.32% -26.43% -20.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $450.1K $525.6K $450.1K
YoY Change 5.48% 119.01% 5.48%
Accrued Expenses $1.288M $784.8K $1.288M
YoY Change -2.15% 10.54% -2.15%
Deferred Revenue $40.00 $84.12K
YoY Change -99.96%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.764M $1.764M
YoY Change
Total Short-Term Liabilities $3.884M $1.578M $3.884M
YoY Change 109.28% 41.35% 109.28%
LONG-TERM LIABILITIES
Long-Term Debt $889.0K $0.00 $889.0K
YoY Change
Other Long-Term Liabilities $1.500K $0.00 $1.500K
YoY Change -100.0%
Total Long-Term Liabilities $889.0K $0.00 $890.5K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.884M $1.578M $3.884M
Total Long-Term Liabilities $889.0K $0.00 $890.5K
Total Liabilities $4.774M $1.578M $4.774M
YoY Change 157.26% 35.82% 157.26%
SHAREHOLDERS EQUITY
Retained Earnings -$56.13M -$45.41M
YoY Change 23.93% 21.69%
Common Stock $57.96M $57.54M
YoY Change 12.06% 4639978.95%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K $6.464K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $6.426M $9.436M $1.825M
YoY Change
Total Liabilities & Shareholders Equity $6.599M $11.10M $6.599M
YoY Change -20.32% -26.43% -20.32%

Cashflow Statement

Concept 2019 Q4 2019 Q1 2019
OPERATING ACTIVITIES
Net Income -$2.762M -$2.598M -$10.71M
YoY Change 2.58% 10.77% 3.84%
Depreciation, Depletion And Amortization $24.44K $21.63K $95.12K
YoY Change 17.22% 48.14% 36.51%
Cash From Operating Activities -$2.644M -$3.120M -$10.34M
YoY Change 5.22% 37.72% 7.66%
INVESTING ACTIVITIES
Capital Expenditures -$13.73K $5.404K $51.99K
YoY Change 44.53% -91.68% -59.02%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$13.73K -$5.404K -$51.99K
YoY Change 44.53% -91.68% -59.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.600M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.795M 5.818M 8.318M
YoY Change -9382.46% 66.83% 149.24%
NET CHANGE
Cash From Operating Activities -2.644M -3.120M -10.34M
Cash From Investing Activities -13.73K -5.404K -51.99K
Cash From Financing Activities 2.795M 5.818M 8.318M
Net Change In Cash 137.1K 2.693M -2.075M
YoY Change -105.37% 132.73% -67.55%
FREE CASH FLOW
Cash From Operating Activities -$2.644M -$3.120M -$10.34M
Capital Expenditures -$13.73K $5.404K $51.99K
Free Cash Flow -$2.630M -$3.125M -$10.39M
YoY Change 5.07% 34.12% 6.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
378239
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
40
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
106609
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1855687
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
888961
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
41
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
51721834
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10405609
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
113631
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-0944526
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4465455
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
424287
CY2019Q4 us-gaap Inventory Net
InventoryNet
439533
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
820206
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6149481
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
75000
CY2018Q4 myo Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
144582
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-10713009
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-10316739
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
553782
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
409746
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.35
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-25.18
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
12445778
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-74213
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2
CY2018 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
3556391
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
814666
CY2019 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-123447
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5603829
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-80250
CY2019 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-72
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15
CY2019Q4 us-gaap Liabilities
Liabilities
4773985
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
57
CY2019 us-gaap Operating Expenses
OperatingExpenses
13715110
CY2018 us-gaap Operating Expenses
OperatingExpenses
12244242
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-10795003
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
676703
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
36169
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
574524
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
415006
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
574497
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
414979
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2018Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2019 us-gaap Gross Profit
GrossProfit
2920107
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2160588
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1838633
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11554522
CY2019 dei Entity File Number
EntityFileNumber
001-38109
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
One Broadway
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
14 th Floor
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2019 dei City Area Code
CityAreaCode
617
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2019 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2018 us-gaap Gross Profit
GrossProfit
1715825
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56125982
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1824708
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6598693
CY2018Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1990
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3883529
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
187513
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1743427
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45289526
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
57957097
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6425885
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8281572
CY2019Q4 myo Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
219240
CY2019 dei Local Phone Number
LocalPhoneNumber
996-9058
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6540794
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
382258
CY2018Q4 us-gaap Inventory Net
InventoryNet
256149
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
695276
CY2018Q4 us-gaap Assets Current
AssetsCurrent
7874477
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
75000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
154972
CY2019Q4 us-gaap Assets
Assets
6598693
CY2018Q4 us-gaap Assets
Assets
8281572
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1763887
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1738450
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3661
CY2019Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2913
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1495
CY2018Q4 us-gaap Liabilities
Liabilities
1855687
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
917623
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2444104
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
728279
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3837730
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1140
CY2019 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-194485
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-175409
CY2018 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-36269
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
211678
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-10528417
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
81994
CY2019 myo Put Option Bifurcated From Term Loan
PutOptionBifurcatedFromTermLoan
372827
CY2019 myo Conversion Of Accrued Interest To Principal
ConversionOfAccruedInterestToPrincipal
65270
CY2018 us-gaap Profit Loss
ProfitLoss
-10316739
CY2019 myo Warrants Issued As Offering Costs And Recorded As Derivative Liability
WarrantsIssuedAsOfferingCostsAndRecordedAsDerivativeLiability
196236
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
907993
CY2019 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
710572
CY2019 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
1836
CY2018 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
760
CY2019 us-gaap Profit Loss
ProfitLoss
-10713009
CY2019 us-gaap Depreciation
Depreciation
95124
CY2018 us-gaap Depreciation
Depreciation
69682
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
907993
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
814666
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2481
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
16275
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
58296
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
-71265
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
32645
CY2019 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
194485
CY2018 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
36269
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9423
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
42028
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
101494
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
213562
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
140817
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
163742
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
307001
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
87265
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
60742
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
466191
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2418
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-103340
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-106569
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-109
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10341817
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9606310
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51991
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
126867
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51991
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-126867
CY2019 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2788019
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5603829
CY2018 myo Proceeds From Payments For Issuance Costs
ProceedsFromPaymentsForIssuanceCosts
-144582
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
80322
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
74213
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3556391
CY2019 myo Proceeds From Payments Under Grants
ProceedsFromPaymentsUnderGrants
6928
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8318469
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3337598
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2075339
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6395579
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6615794
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13011373
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4540455
CY2019 myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
17715
CY2018 myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
53178
CY2019 myo Issuance Of Selling Agent Warrants
IssuanceOfSellingAgentWarrants
196236
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8212; Description of Business</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myomo Inc. (&#8220;Myomo&#8221; or the Company&#8221;) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro &#174; myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class&#160;II medical device. The Company sells the product to orthotics and prosthetics (O&amp;P) providers, the Veterans Health Administration (VA), rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, utilizing the clinical services of O&amp;P providers for which they are paid a fee. The Company was incorporated in the State of Delaware on September&#160;1, 2004 and is headquartered in Cambridge, Massachusetts.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to an amended and restated certificate of incorporation, the Company is authorized to issue up to 125,000,000 shares of stock, consisting of 100,000,000 shares of common stock, par value $0.0001 and 25,000,000 shares of undesignated Preferred Stock, par value of $0.0001.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shelf Registration Statement</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2018, the Company filed a Registration Statement on Form S-3 (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, warrants and/or units or any combination thereof the Company (collectively, the &#8220;Securities&#8221;) having an aggregate price of up to $75 million, subject to the limitations of the Shelf. The Company simultaneously entered into an At Market Issuance Sales Agreement (the &#8220;Sales Agreement&#8221;) with B. Riley FBR, Inc., as sales agent, to provide for the offering, issuance and sale by the Company of up to an aggregate amount of $15 million of the Company&#8217;s common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf and subject to the limitations thereof. The Company shall pay to the sales agent cash commissions of 3.0% of the gross proceeds of sales of common stock under the Sales Agreement.&nbsp;&nbsp;The Sales Agreement was suspended following the Company&#8217;s follow-on public offering in February 2019.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-on Public Offerings</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed a follow-on offering of 1,660,000 shares of its common stock and 1,660,000 investor warrants to purchase one share of the Company&#8217;s common stock at a combined offering price of $7.00 per share.&nbsp;&nbsp;In addition, the Company sold 483,000 pre-funded warrants and 483,000 investor warrants to purchase one share of the Company&#8217;s common stock at a combined offering price of $6.999 per share. The offering generated approximately $13.7 million in net proceeds to the Company.&nbsp;&nbsp;See Note 13 &#8211; Subsequent Events, for further information.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company completed a follow-on offering of 151,417 shares of its common stock, including the underwriter&#8217;s exercise of its over-allotment option, generating net proceeds of approximately $5.6 million. See Note 7 &#8211; Common Stock, for further information.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Term Loan</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 22, 2019, the Company entered into a Note Purchase Agreement, Senior Note and Security Agreement (collectively, the &#8220;Term Loan&#8221;) with Chicago Venture Partners (&#8220;CVP &#8220;or &#8220;Lender&#8221;). Under the Term Loan, the Company received gross proceeds of $3.0 million, excluding fees and expenses. Including an original issue discount, the Company will repay the Lender $3.3 million.&nbsp;&nbsp;See Note 6 &#8211; Debt, for further information</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net losses of approximately $10,713,000&#160;and $10,317,000&#160;during the years ended December&#160;31, 2019 and 2018, respectively, and has an accumulated deficit of approximately $56,126,000 and $45,290,000<font style="font-size:11pt;">&#160;</font>at December&#160;31, 2019 and 2018, respectively. Cash used in operating activities was approximately $10,342,000<font style="font-size:11pt;">&#160;</font>and $9,606,000<font style="font-size:11pt;">&#160;</font>for the years ended December&#160;31, 2019 and 2018, respectively.&nbsp;&nbsp;The Company has historically funded its operations through financing activities, including raising equity and debt capital.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the notes to the Company&#8217;s audited financial statements as of and for the year ended December 31, 2018, and subsequently in each of the Company&#8217;s quarterly unaudited condensed financial statements, management stated the Company had incurred significant losses, negative operating cash flows and as of those dates needed to raise additional capital to meet its obligations and sustain its operations.&nbsp;&nbsp;As a result, the Company concluded that there was substantial doubt as to the Company&#8217;s ability to continue as a going concern.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed a follow-on offering of its common stock, generating net proceeds of approximately $13.7 million. The Company believes the funds raised will allow the Company to execute on its strategy towards achieving cash flow breakeven.&nbsp;&nbsp;Based upon its expected cash flows and the funds raised in the February 2020 equity offering, the Company believes that its available cash will fund its operations for at least the next twelve months from the issuance date of these financial statements.&nbsp;&nbsp;As a result of the net proceeds raised in the February 2020 equity offering and after consideration of management&#8217;s plans described below, the Company believes that substantial doubt about the Company&#8217;s ability to continue as a going concern has been alleviated.&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s operating plans are primarily focused on scaling up its operations, increasing the proportion of patients carrying commercial health insurance with payers that have historically reimbursed for the Company&#8217;s products, executing on its plans to bring its pediatric product to market on schedule and continued work with the Centers for Medicare and Medicaid Services, or CMS, and their billing contractors regarding reimbursement of its products. In addition, the Company believes that it has access to capital resources through possible public or private equity offerings, including usage of its ATM facility, exercises of outstanding warrants, additional debt financings, or other means.&nbsp;&nbsp;Additional debt financing requires the consent of CVP and may require the Company to pledge other assets not currently pledged and enter into covenants that could restrict certain business activities or its ability to incur further indebtedness; and may contain other terms that are not favorable to the Company or its stockholders. </p>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company&#8217;s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, valuation of stock-based compensation, valuation of embedded derivative liabilities, warranty obligations and reserves for slow-moving inventory.</p>
CY2019Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
125000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019 us-gaap Substantial Doubt About Going Concern Managements Plans Substantial Doubt Alleviated
SubstantialDoubtAboutGoingConcernManagementsPlansSubstantialDoubtAlleviated
As a result of the net proceeds raised in the February 2020 equity offering and after consideration of management’s plans described below, the Company believes that substantial doubt about the Company’s ability to continue as a going concern has been alleviated.
CY2019 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
450101
CY2018Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
426727
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
889583
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1027757
CY2019Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
142804
CY2018Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
73722
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
81981
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
92000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173981
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
123221
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1738450
CY2018Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1743427
CY2018 myo Reimbursable Expense Cost
ReimbursableExpenseCost
31600
CY2019Q1 us-gaap Inventory Net
InventoryNet
171514
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
656464
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45412973
CY2019 myo Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Ultimate Settlement
IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponUltimateSettlement
0.50
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
814666
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
907993
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
222036
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
195733
CY2019 us-gaap Advertising Expense
AdvertisingExpense
301700
CY2018 us-gaap Advertising Expense
AdvertisingExpense
136300
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
46854
CY2019Q4 myo Inventory Rental Units
InventoryRentalUnits
23418
CY2018Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
135635
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
287631
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
192277
CY2019Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
372996
CY2018Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
195514
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
443268
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
331149
CY2019Q4 myo Inventory Reserve For Rental Units
InventoryReserveForRentalUnits
-3735
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
24000
CY2018Q4 myo Inventory Reserves Under Consignment
InventoryReservesUnderConsignment
51000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
347249
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100118
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3964250
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6037456
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
39930
CY2018 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-36269
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
3661
CY2019 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
196236
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
372827
CY2019 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-194485
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
378239
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12300
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
12506
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
454
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
188
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
39
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24125
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6033
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4236
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3786
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
331
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21805
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11223
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13763
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.9600
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
92.1000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
93.3000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
50.7000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
116.1000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
72.6000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
31.7700
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
69.0200
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
72.9700
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.0500
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
63.0000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
58.5000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
70.2800
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M24D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M3D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M29D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M26D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M1D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
732399
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
157260
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17581
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
141506
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
17581
CY2019 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2018 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
57.37
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
53.10
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6255
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6103
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0216
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0288
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M15D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M29D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
209248
CY2018 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
-40185
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
169063
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
12113
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
181176
CY2017Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
206465
CY2018 myo Class Of Warrant Or Right Previously Issued Warrants Which Became Exerciseable
ClassOfWarrantOrRightPreviouslyIssuedWarrantsWhichBecameExerciseable
2783
CY2018 myo Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
-40185
CY2018Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
169063
CY2019 myo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
12113
CY2019Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
181176
CY2017Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
115.50
CY2018 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Previously Issued Warrants Which Became Exerciseable In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPreviouslyIssuedWarrantsWhichBecameExerciseableInPeriodWeightedAverageExercisePrice
72.00
CY2018 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice
88.50
CY2018Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
121.50
CY2019 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
52.50
CY2019Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
86.40
CY2017Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
115.80
CY2018 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Previously Issued Warrants Which Became Exerciseable In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPreviouslyIssuedWarrantsWhichBecameExerciseableInPeriodWeightedAverageExercisePriceExercisable
72.00
CY2018 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable
88.50
CY2018Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
121.80
CY2019 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePriceExercisable
52.50
CY2019Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
86.40
CY2019 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
51700
CY2019Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
25900
CY2018Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
490500
CY2019Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
47400
CY2018Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
54300
CY2019 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company has a month-to-month lease agreement for office space in Cambridge, MA and a six-month lease arrangement for office space in Fort Worth, TX.
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
542600
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
352800
CY2019 myo Product Warranty Period
ProductWarrantyPeriod
P3Y
CY2016 myo Product Warranty Period
ProductWarrantyPeriod
P1Y
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
92000
CY2017Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
50725
CY2019 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
4174
CY2018 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
23452
CY2019 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
29227
CY2018 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
38382
CY2019 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
43420
CY2018 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
20559
CY2018 myo Federal State And Local Income Tax Expense Benefit
FederalStateAndLocalIncomeTaxExpenseBenefit
-2636000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-2902000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
81981
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2196000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2065000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-706000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-571000
CY2019 myo Federal State And Local Income Tax Expense Benefit
FederalStateAndLocalIncomeTaxExpenseBenefit
-2902000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-2636000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0557
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0557
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
0.0122
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
-0.0003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0070
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0098
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2709
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2556
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11378000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8378000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
173000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
178000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
28000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
27000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
346000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
440000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11925000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9023000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11925000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9023000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001564590-20-010809-index-headers.html Edgar Link pending
0001564590-20-010809-index.html Edgar Link pending
0001564590-20-010809.txt Edgar Link pending
0001564590-20-010809-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ge2c5wxvrw32000001.jpg Edgar Link pending
myo-10k_20191231.htm Edgar Link pending
myo-20191231.xml Edgar Link completed
myo-20191231.xsd Edgar Link pending
myo-20191231_cal.xml Edgar Link unprocessable
myo-20191231_def.xml Edgar Link unprocessable
myo-20191231_lab.xml Edgar Link unprocessable
myo-20191231_pre.xml Edgar Link unprocessable
myo-ex231_7.htm Edgar Link pending
myo-ex311_8.htm Edgar Link pending
myo-ex312_11.htm Edgar Link pending
myo-ex321_9.htm Edgar Link pending
myo-ex322_10.htm Edgar Link pending
myo-ex47_213.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending